Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP:BICX)

0.3200 -0.0800 (-20.00%)
Streaming Delayed Price Updated: 2:05 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biocorrx Inc

< Previous 1 2 3 Next >
News headline image
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Announces Appointment of Louis Lucido as Board Chair
Via TheNewswire.com
News headline image
BioCorRx Announces Appointment of Louis Lucido as Board Chair
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
Via TheNewswire.com
Topics Regulatory Compliance
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
Via TheNewswire.com
BioCorRx Reports Business Update for the First Quarter of 2025
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences; BioCorRx Inc.
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Reports Business Update for the First Quarter of 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
ANAHEIM, CA and LOUISVILLE, KY - March 10, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related... 
Via TheNewswire.com
News headline image
BioCorRx Reports Business Update for the Second Quarter of 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for the First Quarter of 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
ANAHEIM, CA - (NewMediaWire) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today... 
Via TheNewswire.com
Topics Death Intellectual Property
News headline image
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
ANAHEIM, CA - (NewMediaWire) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that... 
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for 2023
ANAHEIM, CA - (NewMediaWire) - April 02, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today... 
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
ANAHEIM, CA - (NewMediaWire) - February 28, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders,... 
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
ANAHEIM, CA - (NewMediaWire) - February 28, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders,... 
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
ANAHEIM, CA - (NewMediaWire) - February 8, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders,... 
Via TheNewswire.com
News headline image
Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying ↗
The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
BioCorRx Reports Business Update for the Third Quarter of 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
News headline image
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.